Biogen Idec Given Consensus Recommendation of “Buy” by Analysts (NASDAQ:BIIB)
Shares of Biogen Idec (NASDAQ:BIIB) have earned a consensus recommendation of “Buy” from the twenty-six ratings firms that are presently covering the company, StockRatingsNetwork reports. Five research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $332.15.
Shares of Biogen Idec (NASDAQ:BIIB) traded down 0.48% on Friday, hitting $298.262. The stock had a trading volume of 173,475 shares. Biogen Idec has a one year low of $194.66 and a one year high of $358.89. The stock’s 50-day moving average is $291.3 and its 200-day moving average is $296.3. The company has a market cap of $70.747 billion and a price-to-earnings ratio of 37.27.
Biogen Idec (NASDAQ:BIIB) last released its earnings data on Wednesday, April 23rd. The company reported $2.47 EPS for the quarter, missing the Thomson Reuters consensus estimate of $2.56 by $0.09. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.00 billion. During the same quarter in the prior year, the company posted $1.80 earnings per share. The company’s quarterly revenue was up 50.5% on a year-over-year basis. On average, analysts predict that Biogen Idec will post $11.50 earnings per share for the current fiscal year.
BIIB has been the subject of a number of recent research reports. Analysts at Zacks reiterated an “outperform” rating on shares of Biogen Idec in a research note on Thursday, May 15th. They now have a $356.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Biogen Idec in a research note on Monday, April 28th. They now have a $380.00 price target on the stock, down previously from $398.00.
In other Biogen Idec news, EVP Steven Holtzman unloaded 1,221 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $289.15, for a total transaction of $353,052.15. Following the completion of the sale, the executive vice president now directly owns 5,749 shares in the company, valued at approximately $1,662,323. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.